Malmö-based Pila Pharma has announced the final outcome of its TO2 warrants. Despite a tough climate where the stock traded below the exercise price, the subscription rate landed at roughly 12 per cent, bringing in SEK 5,4 million. The capital injection tops-up an already solid balance sheet, securing the funding for the full upcoming clinical obesity study and extending the company’s financial runway well into 2027.
Read the full article at biostock.se:
https://biostock.se/en/2026/02/pila-pharma-starker-kassan-och-finansierar-klinisk-fetmastudie/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se